前收市價 | 0.0100 |
開市 | 0.0100 |
買盤 | 0.0100 |
賣出價 | 0.0200 |
拍板 | 5.50 |
到期日 | 2024-05-24 |
今日波幅 | 0.0100 - 0.0100 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 940 |
Cannabis stocks including Tilray, Curaleaf, and the AdvisorShares Pure US Cannabis ETF rallied on Thursday after the U.S. Department of Justice unveiled a historic proposal to ease restrictions on marijuana. Under the proposal, cannabis would be reclassified from a so-called Schedule I drug, which are considered highly additive with no medical benefits, to a Schedule III, signifying it has moderate to low potential for physical and psychological dependence. "No safety concerns were identified in the FDA's review that would indicate that medical use of marijuana poses unacceptably high safety risks," the proposal says.
A change in classification is moving closer to reality. Multistate weed sellers would be the immediate beneficiaries.
If you think this new law will measurably increase marijuana sales, you must be smoking something.